secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001213900-23-025698
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma FY2022 revenue $970K (+173%) but net loss widens to $16.3M
-------------------------------------------------------------------------

- Revenue $969,783 (up 173% from $355,797) driven by contract services with Rgene.
- Net loss $16.3M vs $12.0M in 2021; operating expenses $15.8M (up $3.7M).
- Cash dropped to $85K from $5.8M; working deficit of $2.8M.
- Pipeline: Vitargus Phase II expected completion end of 2023; ABV-1505 ADHD enrollment ongoing.
- ABV-1601 Phase I at Cedars-Sinai initiated; ABV-1504 MDD meeting with FDA for Phase III.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/0001213900-23-025698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023025698/ea176287-8ka_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-025698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer